Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes

Diabetes Care

Volumn 25, Issue 5, 2002, Pages 869-875

  Ahrén, Bo ^a   Simonsson, Erik ^a   Larsson, Hillevi ^a   Landin Olsson, Mona ^a   Torgeirsson, Hlin ^a   Jansson, Per Anders ^b   Sandqvist, Madeléne ^b   Båvenholm, Peter ^c   Efendic, Suad ^c   Eriksson, Jan W ^d   Dickinson, Sheila ^e   Holmes, David ^e  

^a LUND UNIVERSITY   (Sweden)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d UMEÅ UNIVERSITY   (Sweden)

^e NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

6 [[2 [[2 (2 CYANO 1 PYRROLIDINYL) 2 OXOETHYL]AMINO]ETHYL]AMINO]NICOTINONITRILE; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCOSE; HEMOGLOBIN A1C; INSULIN; PLACEBO; UNCLASSIFIED DRUG; GLYCOSYLATED HEMOGLOBIN; NITRILE; NVP-DPP728; PYRROLIDINE DERIVATIVE;

ADULT; AGED; ALLERGIC RHINITIS; ANOREXIA; ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; ENZYME INHIBITION; FEMALE; GLUCOSE BLOOD LEVEL; HIATUS HERNIA; HOARSENESS; HORDEOLUM; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; METABOLIC REGULATION; MULTICENTER STUDY; MUSCLE HYPERTONIA; MUSCLE WEAKNESS; MYALGIA; NAUSEA; NEPHROTIC SYNDROME; NIGHT SWEAT; NON INSULIN DEPENDENT DIABETES MELLITUS; PARESTHESIA; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; SWEATING; TREATMENT OUTCOME; TREMOR; URINARY FREQUENCY; VERTIGO; BLOOD; MIDDLE AGED; TIME;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD26; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INSULIN; MALE; MIDDLE AGED; NITRILES; PYRROLIDINES; TIME FACTORS; TREATMENT OUTCOME;

EID: 0036583164     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.25.5.869     Document Type: Article

References (24)

1. Fehmann HC, Göke R, Göke B: Cell and molecular biology of the incretin hormones glucagon-like peptide-I and glucose-dependent insulin releasing polypeptide. Endocr Rev 16:390-410, 1995
2. Drucker DJ: Glucagon-like peptides. Diabetes 47:159-169, 1998
3. Ahrén B: Glucagon-like peptide 1 (GLP-1) - a gut hormone of potential interest in the treatment of diabetes. BioEssoys 20:642-651, 1998
4. Nauck MA, Holst JJ, Willms B, Schmiegel W: Glucagon-like peptide 1 (GLP-1) as a new therapeutic approach for type 2-diabetes. Exp Clin Endocrinol Diabet 105:187-195, 1997
5. Gutniak M, Ørskov C, Holst J, Ahrén B, Efendic S: Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus. N Engl J Med 326:1316-1322, 1992
6. Gutniak MK, Linde B, Holst JJ, Efendic S: Subcutaneous injection of the incretin hormone glucagon-like peptide 1 abolishes postprandial glycemia in NIDDM. Diabetes Care 17:1039-1044, 1994
7. Nauck MA, Wollschlaeger D, Werner J, Holst JJ, Ørskov C, Creutzfeldt W, Willms B: Effects of subcutaneous glucagon-like peptide 1 (GLP-[7-36amide]) in patients with NIDDM. Diabetologia 39:1546-1553, 1996
8. Gutniak MK, Larsson H, Sanders SW, Juneskans O, Holst JJ, Ahrén B: GLP-1 tablet in type 2 diabetes in fasting and postprandial conditions. Diabetes Care 20:1874-1879, 1997
9. Rachman J, Barrow BA, Levy JC, Turner RC: Near-normalization of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM. Diabetologia 40:205-211, 1997
10. Deacon CF, Johnsen AH, Holst JJ: Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab 80:952-957, 1995
11. Holst JJ, Deacon CF: Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type II diabetes mellitus. Diabetes 47:1663-1670, 1998
12. Mentlein R: Dipeptidyl-peptidase IV (CD26) - role in the inactivation of regulatory peptides. Regul Pept 85:9-24, 1999
13. Kieffer TJ, McIntosh CH, Pederson RA: Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 136:3585-3596, 1995
14. Knudsen LB, Pridal L: Glucagon-like peptide-1-(9-36)amide is a major metabolite of glucagon-like peptide-1-(7-36)amide after in vivo administration to dogs, and it acts as an antagonist on the pancreatic receptor. Eur J Pharmacol 318:429-435, 1996
15. Marguet D, Baggio L, Kobayashi T, Bernard AM, Pierres M, Nielsen PF, Ribel U, Waranabe T, Drucker DJ, Wagtmann N: Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26. Proc Natl Acad Sci U S A 97:6874-6879, 2000
16. Nagakura T, Yasua N, Yamazaki K, Ikuta H, Yoshikawa S, Asano O, Tanaka I: Improved glucose tolerance via enhanced glucose-dependent insulin secretion in dipeptidyl peptidase IV-deficient Fischer rats. Biochem Biophys Res Commun 284:501-506, 2001
17. Deacon CF, Hughes TE, Holst JJ: Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig. Diabetes 47:764-769, 1998
18. Pederson RA, White HA, Schlenzig D, Pauly RP, McIntosh CHS, Demuth HU: Improved glucose tolerance in Zucker fatty rats by oral administration of the dipeptidylpeptidase IV inhibitor isoleucine thiazolidide. Diabetes 47:1253-1258, 1998
19. Balkan B, Kwasnik L, Miserendino R, Holst JJ, Li X: Inhibition of dipeptidyl peptidase IV with NVP DPP728 increases plasma GLP-1 (7-36 amide) concentrations and improves oral glucose tolerance in obese Zucker rats. Diabetologia 42:1324-1331, 1999
20. Ahrén B, Holst JJ, Mårtensson H, Balkan B: Improved glucose tolerance and insulin secretion by inhibition of dipeptidyl peptidase IV in mice. Eur J Pharmacol 404:239-245, 2000
21. Hughes TE, Mone MD, Russell ME, Weldon SC, Villhauer EB: NVP DPP728 (1-[[[2-[(5-cyanopyridin-2-yl)amino]ethyl] amino]acetyl]-2-cyano-(S)- pyrrolidine), a slow-binding inhibitor of dipeptidyl peptidase IV. Biochemistry 38:11597-11603, 1999
22. Juntti-Berggren L, Pigon J, Karpe F, Hamsten A, Gutniak M, Vignati L, Efendic S: The antidiabetogenic effect of GLP-1 is maintained during a 7-day treatment period and improves diabetic dyslipoproteinemia in NIDDM patients. Diabetes Care 19:1200-1206, 1996
23. Edwards CM, Todd JF, Ghatei MA, Bloom SR: Subcutaneous glucagon-like peptide-1 (7-36) amide is insulinotropic and can cause hypoglycemia in fasted healthy subjects. Clin Sci 95:719-724, 1998
24. Singh LK, Pang X, Alexacos N, Letourneau R, Theoharides TC: Acute immobilization stress triggers skin mast cell degranulation via corticotropin releasing hormone, neurotensin, and substance P: a link to neurogenic skin disorders. Brain Behav Immunol 13:225-239, 1999